This commentary explains why comparing a launch price with a value-based price from a cost-effectiveness analysis requires further examination.
Louis P. Garrison Jr, PhD
Advertisement
Articles by Louis P. Garrison Jr, PhD
Assessment of current trends, success factors, and challenges in the use of risk-sharing agreements in the US private sector.
Advertisement
Latest Updated Articles
Challenges With Judging and Interpreting a Drug’s Launch PricePublished: March 24th 2025 | Updated:
- Private Sector Risk-Sharing Agreements in the United States: Trends, Barriers, and Prospects
Published: September 15th 2015 | Updated:
- Toward Evidence-based Assessment for Coverage and Reimbursement of Laboratory-based Diagnostic and Genetic Tests
Published: April 1st 2006 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
2025 Nobel Prize in Medicine Honors Discoveries Behind Regulatory T Cells
2
FDA Expands Roflumilast Use for Atopic Dermatitis to Children Aged 2 to 5 Years
3
Amgen Direct-to-Patient Program Aims to Expand Access to Evolocumab Amid US Drug Pricing Reforms
4
Aggressive Therapy Recommendations Following the STRONG-HF Trials: Stephen J. Green, MD
5
